Valuation: Alamar Biosciences, Inc.

Market Cap 2.36B 2.08B 1.97B 1.78B 3.36B 227B 3.4B 23.6B 9.08B 116B 8.88B 8.68B 372B P/E 2026 *
-28x
P/E 2027 * -49.2x
Enterprise Value 2.18B 1.92B 1.82B 1.64B 3.09B 209B 3.13B 21.73B 8.36B 107B 8.17B 7.99B 342B EV / Sales 2026 *
18.4x
EV / Sales 2027 * 13.3x
Free-Float
77.76%
Yield 2026 *
-
Yield 2027 * -
1 day+4.35%
1 week+6.00%
1 month+11.56%
3 months+25.77%
1 week 31.94
Extreme 31.94
35.28
1 month 27.25
Extreme 27.25
37.76
Current year 18.84
Extreme 18.845
38.54
1 year 18.84
Extreme 18.845
38.54
3 years 18.84
Extreme 18.845
38.54
5 years 18.84
Extreme 18.845
38.54
10 years 18.84
Extreme 18.845
38.54
Manager TitleAgeSince
Chief Operating Officer 63 2018-07-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Chief Executive Officer 62 2018-06-30
Director TitleAgeSince
Chairman 62 2018-06-30
Director/Board Member 64 2020-04-30
Director/Board Member 66 2026-08-27
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Free

General Counsel

114,000 0.1643%
9/1/26 Free

Director

31,285 0.0451%
4/20/26 Others

Director

206,781 --
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+6.00% - - 2.27B
-0.67%+1.47%+39.18%+33.36% 251B
-1.84%-0.00%+11.75%-10.70% 159B
-1.35%+2.09%-9.08%+39.12% 146B
-0.52%-2.17%-55.29%-17.33% 63.59B
-2.00%-0.58%+10.99%+24.60% 50.77B
-1.55%+4.23%+34.25%+54.10% 49.35B
-1.76%+2.07%-17.49%-20.90% 48.75B
+2.47%+5.43%-4.18%+40.30% 45.1B
-0.87%+4.47%+46.56%+60.24% 43.55B
Average -0.37%+1.65%+6.30%+22.53% 85.92B
Weighted average by Cap. -1.01%+1.93%+11.80%+21.73%

Financials

2026 *2027 *
Net sales 119M 104M 98.94M 89.32M 168M 11.37B 171M 1.18B 456M 5.81B 445M 436M 18.63B 166M 146M 138M 125M 235M 15.89B 238M 1.65B 637M 8.12B 622M 609M 26.04B
Net income -64.94M -57.19M -54.18M -48.91M -92.19M -6.23B -93.38M -648M -249M -3.18B -244M -239M -10.21B -49.86M -43.91M -41.6M -37.56M -70.79M -4.78B -71.7M -498M -192M -2.44B -187M -183M -7.84B
Net Debt -188M -165M -157M -141M -266M -17.99B -270M -1.87B -721M -9.2B -705M -689M -29.49B -156M -137M -130M -117M -221M -14.95B -224M -1.56B -599M -7.64B -585M -573M -24.5B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
286
Date Price Change Volume
26-09-30 US$34.07 +4.35% 741,818
26-09-29 US$32.65 +0.12% 1,090,582
26-09-28 US$32.61 -0.58% 224,702
26-09-25 US$32.80 -1.20% 297,265
26-09-24 US$33.20 +3.30% 527,264
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.07USD
Average target price
35.40USD
Spread / Average Target
+3.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock